OGSIVEO®

Hold Company

SPRINGWORKS

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 50MG BASE; EQ 100MG BASE; EQ 150MG BASE

Indication

Ogsiveo® is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Use

Instructions for Use

API

NIROGACESTAT HYDROBROMIDE

API Structure

We Supply

NIROGACESTAT

Drug Patent

Patent No	Expiration Date
10590087	2039/8/9
10710966	2039/8/9
10941118	2039/8/9
11504354	2042/7/8
11612588	2042/7/8
11807611	2042/9/8
11820748	2039/8/9
11844780	2042/9/8
11845732	2039/8/9
11872211	2043/5/19
11884634	2039/8/9
11884635	2039/8/9
11905255	2039/8/9
11925619	2043/5/19
11925620	2043/5/19
11938116	2043/5/19
11951096	2043/5/19
11957662	2043/5/19
12011434	2043/5/19
12011435	2043/5/19
12036207	2043/5/19
12110277	2042/7/8
12116347	2039/8/9
12138246	2043/5/19
12234210	2042/7/8
12247012	2042/7/8
7342118	2025/8/18
7795447	2025/8/18
7951958	2026/3/11

API Patent

Patent No	Expiration Date
11504354	2042/7/8
11612588	2042/7/8
11807611	2042/9/8
11844780	2042/9/8
7342118	2025/8/18
7795447	2025/8/18
7951958	2026/3/11

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.